Company intelligence / Profile preview
Sidero Bioscience
- Ownership
- Private
- Development stage
- Preclinical
Overview
Sidero Bioscience develops patented oral iron supplements based on the Siderosorb platform, which uses a ferritin-based protein complex expressed in yeast to deliver bioavailable iron with fewer gastrointestinal side effects than traditional supplements. Their lead product, BioFe, mimics natural maternal pathways for iron absorption and has shown improved tolerability and efficacy in early clinical studies. The company targets global unmet needs in iron deficiency management and has entered commercialization agreements for India/Southeast Asia.
- Therapeutic areas
- GastroenterologyHematology
- Modalities
- Therapeutic proteins/complexes (ferritin-based)Medical food/nutritional supplement
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Sidero Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sidero Bioscience.